Heat shock factor 1-independent activation of dendritic cells by heat shock: implication for the uncoupling of heat-mediated immunoregulation from the heat shock response
/in Hyperthermia, International Publications /von 2003-06-01 / Eur. J. Immunol. 2003 Jun;33(6):1754-62Doxorubicin activity is enhanced by hyperthermia in a model of ex vivo vascular perfusion of human colon carcinoma
/in Colorectal Cancer, Hyperthermia, International Publications /von 2003-05-13 / World J Surg 2003 Jun;27(6):640-6Ifosfamide, carboplatin and etoposide combined with 41.8 degrees C whole body hyperthermia for malignant pleural mesothelioma
/in Hyperthermia, International Publications, Malignant Pleural Mesothelioma, NSCLC /von 2003-03-01 / Lung Cancer 2003 Mar;39(3):339-45The effect of whole-body hyperthermia combined with ‚metronomic‘ chemotherapy on rat mammary adenocarcinoma metastases
/in Breast Cancer, Hyperthermia, International Publications /von 2003-03-01 / Int J Hyperthermia 2003 Mar-Apr;19(2):103-18Ifosfamide with regional hyperthermia in soft-tissue sarcomas
/in Hyperthermia, International Publications, Soft Tissue Sarcoma /von 2003-01-01 / Oncology 2003;65 Suppl 2:76-9A Systemic Hyperthermia Oncologic Working Group trial. Ifosfamide, carboplatin, and etoposide combined with 41.8 degrees C whole-body hyperthermia for metastatic soft tissue sarcoma
/in Hyperthermia, International Publications, Soft Tissue Sarcoma /von 2003-01-01 / Oncology 2003;64(4):312-21Cancer immunotherapy: stress proteins and hyperthermia
/in Dendritic Cells, Hyperthermia, International Publications /von 2002-11-01 / Int J Hyperthermia 2002 Nov-Dec;18(6):506-20Stimulation of Th1-polarizing cytokines, C-C chemokines, maturation of dendritic cells, and adjuvant function by the peptide binding fragment of heat shock protein 70
/in Hyperthermia, International Publications /von 2002-09-01 / J. Immunol. 2002 Sep;169(5):2422-9[Is total body hyperthermia plus chemotherapy useful in pancreas carcinoma?]
/in Hyperthermia, International Publications, Pancreatic Cancer /von 2002-08-02 / Dtsch. Med. Wochenschr. 2002 Aug;127(31-32):1660IMMUN-ONKOLOGISCHES ZENTRUM KÖLN
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de